FDA clears Olympus' narrow band imaging for bladder cancer biopsy
The FDA has granted 510(k) clearance to Olympus' Narrow Band Imaging technology designed for improved visualization of tumor boundaries in non-muscle-invasive bladder cancer.
The FDA found that the Olympus technology visualized NMIBS lesions in 17 percent more patient when compared with white light, 24 percent additional tumor and 28 percent additional carcinoma in situ.
The new technology can be used in both the office and operating room.
More articles on FDA clearances:
FDA clears Third Eye Panoramic device for colonoscopy
5 GI/endoscopy devices receive FDA 510(k) clearance in September
3 GI/endoscopy devices receive FDA 510(k) clearance in October
© Copyright ASC COMMUNICATIONS 2017. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
- Meridian Surgical Partners adds John Teas as SVP of business development: 4 things to know
- Physician compensation by metropolitan area: 10 facts on the highest- and lowest- cities
- High physician turnover rates prevail in large ACO: 5 things to know
- Nearly 22k US malaria-related hospitalizations reported in 14 years: 7 takeaways
- 5 key points on MACRA for healthcare leaders to note